This view persists without knowledge of the role of nNOS in skeletal muscle contractile function in vivo and has influenced gene therapy approaches to dystrophinopathy, the majority of which do not restore sarcolemmal nNOSμ. The gene discussed is NOS1; the disease is neuromuscular disease caused by qualitative or quantitative defects of dystrophin.